Mohamed Gouda: HER2 loss in not infrequent after treatment with T-DXd
Mohamed Gouda, Clinical Fellow at the University of Texas MD Anderson Cancer Center, shared a post on X about a recent paper he and his colleagues authored published in Clinical Cancer Research:
“Now published in Clinical Cancer Research!
HER2 loss in not infrequent after treatment with T-DXd. Almost one third of treated patients had complete loss and an additional one third had decrease in HER2 IHC score!”
Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, shared this post, adding:
“Super interesting data, confirming something we’re observing more & more in clinic. Leads to 2 main questions: – is the HER2 downregulation leading to resistance, or just an epiphenomenon of T-DXd treatment? – does HER2 expression rebound after some time without T-DXd exposure?”
Authors: Mohamed A. Gouda et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023